Asher Biotherapeutics develops cis-targeted immunotherapies for cancer and infectious disease. Its lead program, etakafusp alfa, is an IL-2 immunotherapy designed to selectively activate CD8+ T cells.
Asher Biotherapeutics develops cis-targeted immunotherapies for cancer and infectious disease. Its lead program, etakafusp alfa, is an IL-2 immunotherapy designed to selectively activate CD8+ T cells.